[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 471
1. Bagwan IN, Cook G, Mudan S, Wotherspoon A: Unusual presentation of metastatic adenocarcinoma. World J Surg Oncol; 2007;5:116
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic adenocarcinoma.
  • In patients with extradrenal tumour, incidental discovery of an adrenal mass necessitates excluding the possibility of metastatic malignancy.
  • CASE PRESENTATION: A 52 year-old female was diagnosed with oesophageal adenocarcinoma and treated with oesophagectomy and adjuvant chemotherapy.
  • Adrenalectomy was performed and histological examination revealed metastatic adenocarcinoma within an adrenal adenoma.
  • CONCLUSION: The present case highlights the unusual behaviour of an oesophageal adenocarcinoma causing metastasis to an adrenocortical adenoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2005 Dec;52(6):785-8 [16410674.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1624-33 [16518827.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1795-9 [11752075.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] AJR Am J Roentgenol. 1996 Oct;167(4):891-2 [8819376.001]
  • [Cites] Surgery. 2004 Dec;136(6):1289-96 [15657589.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4924-9 [15914530.001]
  • (PMID = 17949483.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2100056
  •  go-up   go-down


2. Qayyum A, Mujtaba I: Effects of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder. J Pak Med Assoc; 2007 Feb;57(2):71-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder.
  • OBJECTIVE: To evaluate the effect of combination chemotherapy on disease status, toxicity and survival of patients with unresectable locally advanced or metastatic adenocarcinoma of gallbladder.
  • METHODS: Single arm study of twenty patients, with unresectable locally advanced or metastatic adenocarcinoma of gallbladder, who presented to oncology clinic at Ziauddin Hospital Nazimabad Karachi from January 1997 to December 1998.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17370788.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Mazeron JJ, Simon JM, Toubiana T, Lang P: [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate]. Bull Cancer; 2005 Dec;92(12):1078-84
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate].
  • Non metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy.
  • Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormono therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396754.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


Advertisement
4. Shidham VB, Varsegi G, D'Amore K: Two-color immunocytochemistry for evaluation of effusion fluids for metastatic adenocarcinoma. Cytojournal; 2010;7:1
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-color immunocytochemistry for evaluation of effusion fluids for metastatic adenocarcinoma.
  • They were unequivocally positive for metastatic adenocarcinoma based on clinical correlation, cytomorphology, and one color immunocytochemistry on cell block sections.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Oct 25;93(5):293-308 [11668464.001]
  • [Cites] Diagn Cytopathol. 1999 Feb;20(2):57-62 [9951597.001]
  • [Cites] Clin Lab Med. 1998 Sep;18(3):561-83 [9742383.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):61-6 [11782091.001]
  • (PMID = 20333313.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2841748
  • [Keywords] NOTNLM ; Serous effusion / dual immunostaining / immunocytochemistry / immunohistochemistry / metastasis / serous cavity / serous fluid / two-colour immunostaining
  •  go-up   go-down


5. Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med; 2007 Oct;131(10):1561-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
  • CONTEXT: Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult.
  • OBJECTIVE: To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin.
  • Results were validated using 60 cases of metastatic adenocarcinoma with known primaries.
  • Overall, these combined phenotypes correctly predicted the tester samples (metastatic adenocarcinomas with known primaries) in 75% of cases.
  • CONCLUSIONS: Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Neoplasm Proteins / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922593.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


6. Taweevisit M, Chirakalwasan N, Pumsuk U, Keelawat S, Shuangshoti S: Metastatic adenocarcinoma to the cervical lymph node: a significant proportion of cholangiocarcinoma in Thai patients. Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):39-41
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma to the cervical lymph node: a significant proportion of cholangiocarcinoma in Thai patients.
  • OBJECTIVE: To determine distribution of the primary site of metastatic adenocarcinoma to the cervical lymph node in Thai population with histological correlation.
  • MATERIALS AND METHODS: 72 Thai patients with metastatic adenocarcinoma to the cervical lymph node were retrospectively analyzed.
  • Metastatic cholangiocarcinoma typically produced distinct glandular pattern, and frequently involved the right supraclavicular lymph node.
  • Brush border of the gland-forming tumor cells was a consistent finding in metastatic cholangiocarcinoma, with 100% sensitivity and 97% specificity.
  • [MeSH-major] Adenocarcinoma / secondary. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / secondary. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439070.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


7. Shelly MJ, Dheer S, Kavanagh EC: Metastatic adenocarcinoma of the lung mimicking mucoid degeneration of the anterior cruciate ligament. Ir J Med Sci; 2010 Jun;179(2):309-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the lung mimicking mucoid degeneration of the anterior cruciate ligament.
  • We report a case of a 63-year-old male with known adenocarcinoma of the lung who presented with knee pain which was initially diagnosed as mucoid degeneration of the anterior cruciate ligament (ACL) on magnetic resonance imaging (MRI).
  • Due to persistent knee pain an interval MRI was performed, followed by image guided biopsy which showed metastatic adenocarcinoma of the lung infiltrating the ACL.
  • [MeSH-major] Adenocarcinoma / pathology. Anterior Cruciate Ligament / pathology. Knee Joint / pathology. Lung Neoplasms / pathology. Mucins / analysis. Soft Tissue Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):312-5 [11465770.001]
  • [Cites] Skeletal Radiol. 2004 Jun;33(6):359-62 [14997351.001]
  • [Cites] Acta Radiol. 2008 Feb;49(1):75-9 [18210315.001]
  • [Cites] J Bone Joint Surg Am. 1992 Mar;74(3):435-7 [1548272.001]
  • [Cites] J Rheumatol. 1977 Spring;4(1):65-72 [886554.001]
  • [Cites] Joint Bone Spine. 2002 Oct;69(5):495-8 [12477235.001]
  • [Cites] Arthroscopy. 1999 Jan-Feb;15(1):98-102 [10024041.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1283-7 [15100133.001]
  • [Cites] J Bone Joint Surg Br. 1999 Mar;81(2):304-5 [10204939.001]
  • (PMID = 19288177.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


8. Oshiro S, Tsugu H, Komatsu F, Abe H, Ohmura T, Sakamoto S, Fukushima T: Metastatic adenocarcinoma in the brain: magnetic resonance imaging with pathological correlations to mucin content. Anticancer Res; 2008 Jan-Feb;28(1B):407-13
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma in the brain: magnetic resonance imaging with pathological correlations to mucin content.
  • BACKGROUND: Hypointense signal appearance of metastatic adenocarcinoma on T2-weighted imaging (T2-WI) has been infrequently documented.
  • PATIENTS AND METHODS: This series of 24 cases with intracerebral metastatic adenocarcinoma was assessed retrospectively, focusing on the association between hypointense appearance on T2-WI and intratumoral mucin content.
  • RESULTS: Among the 24 metastatic adenocarcinomas, intratumoral mucin was histopathologically confirmed in 8 lesions.
  • No cases were identified with hypointense signals in mucin-containing metastatic adenocarcinoma.
  • Conversely, only 2 metastatic tumors originating from the stomach exhibited hypointense signal lesions on T2-WI.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Magnetic Resonance Imaging / methods. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383877.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


9. Resto VA, Krane JF, Faquin WC, Lin DT: Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin. Ann Otol Rhinol Laryngol; 2006 Jan;115(1):59-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical distinction of intestinal-type sinonasal adenocarcinoma from metastatic adenocarcinoma of intestinal origin.
  • OBJECTIVES: Distinction of intestinal-type sinonasal adenocarcinoma (ITAC) from adenocarcinoma of intestinal origin metastatic to the sinonasal cavity may be extremely difficult on histologic grounds alone.
  • We studied the role of cytokeratin (CK) and mucin (MUC) expression in differentiating ITAC, metastatic adenocarcinoma of intestinal origin, and non-intestinal-type sinonasal adenocarcinoma (non-ITAC).
  • METHODS: We stained specimens from 5 cases of ITAC and 4 cases of non-ITAC, along with 4 colonic and 3 duodenal adenocarcinoma controls, with CK7 and CK20, MUC2 and MUC5, neuron-specific enolase (NSE), chromogranin (CHR), and carcinoembryonic antigen (CEA) in order to examine the possible combinations of markers that best aid in the diagnosis of these lesions.
  • RESULTS: CK7 staining was positive in all ITAC and non-ITAC cases, whereas all cases displaying gastrointestinal-type differentiation (ITAC and metastatic intestinal cases) stained positive for both CK20 and MUC2.
  • CONCLUSIONS: Tumors with the CK7+, CK20+, MUC2+ immunophenotype are likely primary sinonasal lesions, whereas tumors with the CK7-, CK20+, MUC2+ profile warrant further clinical evaluation to exclude metastatic disease from the gastrointestinal tract.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Duodenal Neoplasms / metabolism. Keratins / metabolism. Mucins / metabolism. Paranasal Sinus Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466101.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


10. Karabork A, Kaygusuz G, Ekinci C: The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. Pathol Res Pract; 2010 Aug 15;206(8):572-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
  • It can be difficult to differentiate hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA).
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / pathology. Immunohistochemistry / methods. Liver Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20400233.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Veshapidze N, Alibegashvili M, Gabunia N, Ramishvili L, Kotrikadze N: Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate. Georgian Med News; 2009 Jan;(166):9-12
Hazardous Substances Data Bank. SODIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate.
  • The aim of our study was to investigate the alterations of the erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate before and six months after castration.
  • For experimental research were used the erythrocytes of 15 men with metastatic prostate cancer (Pca) (before and after 6 months from castration) and of the 15 practically healthy men (control group).
  • Investigations revealed the changes of Na(+)/K(+)-ATP-ase activity and the changes of Na(+) and K(+) ions concentration in metastatic Pca patients before and six months after castration.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Membrane Permeability / physiology. Erythrocyte Membrane / metabolism. Prostatic Neoplasms / metabolism. Sodium-Potassium-Exchanging ATPase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202209.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 9NEZ333N27 / Sodium; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; RWP5GA015D / Potassium
  •  go-up   go-down


12. Hill HC: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2008 Dec;100(12):1469-73
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma.
  • Treatment is based upon the results of several diagnostic radiographic modalities that may locate the occult primary and determine the extent of metastatic tumor burden.
  • We describe metastatic adenocarcinoma of unknown primary presenting as a pericardial effusion and coincident supraclavicular adenopathy.
  • The patient completed the chemotherapy and had stable metastatic tumor burden with an acceptable quality of life.
  • Although immunohistochemical staining initially suggested metastatic breast carcinoma, her clinical course confirmed a lung primary.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Med Assoc. 2009 May;101(5):478 [19476202.001]
  • (PMID = 19110917.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


13. Marginean EC, Torlakovic G, Neufeld H, Torlakovic E: Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors.
  • Its protein expression in colonic adenocarcinoma has not been systematically evaluated and small number of samples was previously reported as negative.
  • METHODS: Forty cases of colorectal adenocarcinoma were evaluated.
  • The benign colonic mucosa and the matching metastatic tumors of the same patients were also included in the study.
  • RESULTS: GATA-4 was expressed in 32% of colorectal adenocarcinoma, but not in benign colonic mucosa (p=0.0001, Chi-Square).
  • GATA-4 was also significantly more expressed in metastatic (41%) than in primary (21%) colorectal adenocarcinoma (p<0.0001, Chi-Square).
  • While there was no difference in NF-B activation between primary vs. metastatic adenocarcinoma, a strong positive association between GATA-4 expression and NF-B activation (p<0.0001, Linear-by- Linear) was found.
  • GATA-4 may have a role in colorectal adenocarcinoma development and progression and it should be further evaluated in prospective studies as a putative adverse prognostic factor in colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Benjamin H, Lebanony D, Tabak S, Barabash N, Gibori H, Morgenstern S, Meiri E, Bentwich Z, Rosenwald S, Cohen D: MicroRNA-based assay for differential diagnosis of mesothelioma. J Clin Oncol; 2009 May 20;27(15_suppl):e22079

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelioma can be difficult to differentiate from other tumors in the lung or pleura such as primary lung adenocarcinoma presenting with pleural effusion or metastatic adenocarcinoma from extrathoracic sites.
  • RESULTS: We identified microRNAs that are differentially expressed between mesothelioma, lung adenocarcinoma, and other confounding tumor types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963221.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. El-Rayes BF, Patel B, Zalupski M, Hammad N, Shields A, Heilbrun L, Venkatramanamoorthy R, Philip P: A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The primary endpoint was time to progression (TTP) in patients with locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction treated with docetaxel, oxaliplatin and bevacizumab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Costello MR, Meropol NJ, Denlinger CS, Engstrom PF, Wright JJ, Li T, Mclaughlin S, Beard M, Cimildoro R, Cohen SJ: A phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135). J Clin Oncol; 2009 May 20;27(15_suppl):e15605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135).
  • : e15605 Background: There is currently no standard therapy for recurrent or metastatic cancers of the bile duct or gallbladder and available chemotherapy is of uncertain benefit.
  • As activation of NF-κB has been described in these tumors, we initiated a phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic disease.
  • METHODS: Patients with measurable metastatic or unresectable adenocarcinoma of the bile duct or gallbladder who had received up to 2 prior chemotherapy regimens were eligible.
  • CONCLUSIONS: Bortezomib is not an active agent in the treatment of metastatic gallbladder or biliary tract cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962683.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Prowda J, Schreibman S, Levitz J: Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.
  • Based on these findings, we pursued a prospective clinical trial evaluating the activity of GTX in previously untreated patients with metastatic pancreatic cancer.
  • METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.
  • CONCLUSIONS: The combination of gemcitabine, docetaxel, and capecitabine has activity in metastatic pancreatic cancer with a median survival over 1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kim K, Jang GD, Lim HS, Kim HS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW: Pharmacokinetic and pharmacogenetic study of S-1 in Korean patients with metastatic biliary cancer. J Clin Oncol; 2009 May 20;27(15_suppl):2505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic and pharmacogenetic study of S-1 in Korean patients with metastatic biliary cancer.
  • We evaluated associations of genetic variants of CYP2A6 with PK/PD of S-1 when combined with oxaliplatin in metastatic biliary cancer.
  • METHODS: This is a prospective study of patients with histologically confirmed metastatic adenocarcinoma of the biliary tract.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Gutiérrez Macías A, Lizarralde Palacios E, Merino Múgica JM, Cabeza García S, Martínez Odriozola P, Miguel de la Villa F: [Bilateral chylothorax in a case of metastatic adenocarcinoma of unknown primary]. An Med Interna; 2006 Apr;23(4):176-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral chylothorax in a case of metastatic adenocarcinoma of unknown primary].
  • [Transliterated title] Quilotórax bilateral en un caso de adenocarcinoma metastásico de primario desconocido.
  • Necropsy showed widespread metastatic adenocarcinoma of unknown primary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Chylothorax / etiology. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796411.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Schwartz RA, Rothenberg J: Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease. J Cutan Pathol; 2010 Dec;37(12):1251-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease.
  • Metastatic breast cancer of skin may be seen in a number of forms.
  • We describe a patient with metastatic adenocarcinoma of breast within a benign melanocytic nevus and delineate this occurrence within the context of reviewing cutaneous breast metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 20002237.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


21. Mason AC, Azari KK, Farkas LM, Duvvuri U, Myers EN: Metastatic adenocarcinoma of the colon presenting as a mass in the mandible. Head Neck; 2005 Aug;27(8):729-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the colon presenting as a mass in the mandible.
  • BACKGROUND: Metastatic adenocarcinoma of the colon is a frequently encountered medical situation.
  • Metastasis to the mandible from adenocarcinoma of the colon is very unusual and rarely reported.
  • We report the case of a 73-year-old man with metastatic adenocarcinoma to the mandible.
  • RESULTS: A biopsy of the mass in the mandible was performed, and metastatic adenocarcinoma of colonic origin was diagnosed.
  • CONCLUSIONS: Although rare, metastatic adenocarcinoma from the colon to the mandible and parotid area should be included in the differential diagnosis of masses in this area.
  • After analysis of our case and a review of the literature, we conclude that metastasis from adenocarcinoma of the colon is quite rare and represents incurable disseminated disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Mandibular Neoplasms / diagnosis. Mandibular Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 15920751.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Tatokoro M, Kawakami S, Yonese J, Fujii Y, Okubo Y, Yamamoto S, Takeshita H, Komai Y, Ishikawa Y, Fukui I: Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. Int J Urol; 2008 Sep;15(9):851-3
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.
  • We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.
  • From April 1995 to November 2004, four patients with adenocarcinoma of the urachus who developed metastases after definitive surgery were treated with the IFEP chemotherapy followed by consolidative radiotherapy or salvage surgery in good responders.
  • We have demonstrated the IFEP chemotherapy is one of the most effective chemotherapy regimens against metastatic adenocarcinoma of the urachus.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786207.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Kumar R, Deopujari CE, Shah R, Kumar A: Metastatic adenocarcinoma of bilateral cavernous sinus and optic nerve with unknown primary mimicking orbital pseudotumor. Neurol India; 2009 Jan-Feb;57(1):82-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of bilateral cavernous sinus and optic nerve with unknown primary mimicking orbital pseudotumor.
  • We report an extremely rare case of metastatic adenocarcinoma of bilateral cavernous sinus and optic nerve with unknown primary presenting as orbital pseudotumor.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cavernous Sinus / pathology. Optic Nerve Neoplasms / pathology. Optic Nerve Neoplasms / secondary. Orbital Pseudotumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19305087.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


24. Soini Y, Kinnula V, Kahlos K, Pääkkö P: Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol; 2006 Mar;59(3):250-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.
  • AIM: To study the expression of claudins in mesothelioma and metastatic pleural adenocarcinoma.
  • METHODS: Immunohistochemical staining of claudins 1, 2, 3, 4, 5, and 7 was studied in 35 malignant mesotheliomas and the expression compared with 24 cases of pleural metastatic adenocarcinoma.
  • RESULTS: Claudin 1, 2, 3, 4, 5, and 7 expression was seen in 40%, 80%, 18%, 23%, 14%, and 43% of mesotheliomas, respectively, while the corresponding figures for adenocarcinoma were 100%, 88%, 90%, 100%, 50%, and 92%.
  • Claudins 1, 3, 4, 5, and 7 were significantly less positive in mesothelioma than in metastatic adenocarcinoma, while no difference was observed for claudin 2.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Membrane Proteins / analysis. Mesothelioma / pathology. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):476-87 [12110008.001]
  • [Cites] Virchows Arch. 2002 Jul;441(1):41-6 [12111199.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):662-8 [12194995.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1620-6 [12459629.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Jul;29(1):62-70 [12600828.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1166-78 [12909588.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H1917-38 [12842817.001]
  • [Cites] J Pathol. 2003 Nov;201(3):355-62 [14595746.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1155-62 [14652817.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):36-47 [15051488.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] J Cell Biol. 1988 Oct;107(4):1575-87 [3049625.001]
  • [Cites] J Cell Biol. 1992 Apr;117(2):415-25 [1373144.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • (PMID = 16505274.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / CLDN7 protein, human; 0 / Calbindin 2; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudin-5; 0 / Claudins; 0 / Membrane Proteins; 0 / S100 Calcium Binding Protein G
  • [Other-IDs] NLM/ PMC1860350
  •  go-up   go-down


25. Millaire M, Alobaid A, Gariépy G, Gauthier P: Metastatic adenocarcinoma of the cervix: a case report. J Obstet Gynaecol Can; 2005 Dec;27(12):1113-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the cervix: a case report.
  • BACKGROUND: Adenocarcinoma metastatic to the cervix is unusual.
  • CASE: We report the case of a 75-year-old woman with a metastasis to the cervix from a large bowel adenocarcinoma that had been managed by right hemicolectomy 14 months previously.
  • CONCLUSION: In women with cervical adenocarcinoma and a history of gastrointestinal or breast cancer or melanoma, specific screening should be undertaken to ensure that the cervical disease is not metastatic.
  • The detection of adenocarcinoma in this subset of patients might be an indication of recurrent disease.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Uterine Cervical Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524530.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


26. Saleh HA, El-Fakharany M, Makki H, Kadhim A, Masood S: Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis. Diagn Cytopathol; 2009 May;37(5):324-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
  • Differentiating reactive mesothelial cells (RMs) from metastatic adenocarcinoma cells (MAC) in serous fluids based on cytomorphologic features alone can be very challenging.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Body Fluids / cytology. Epithelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19191294.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down


27. Pawar A, Schlader E, Mac-Thiong JM, Maurais G, Dion D, Bédard D: Rare metastatic adenocarcinoma to the spine infiltrating three adjacent foramen in lumbar vertebrae. Orthopedics; 2010 Dec;33(12):928

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare metastatic adenocarcinoma to the spine infiltrating three adjacent foramen in lumbar vertebrae.
  • Computed tomography-guided biopsy confirmed the diagnosis of metastatic adenocarcinoma.
  • But a large retroperitoneal metastatic mass from an unknown primary adenocarcinoma is a rare condition.
  • No reports exist in the literature on a metastatic mass infiltrating vertebral bodies and then entering the epidural space through the 3 consecutive neural foramen.
  • Thus, the pathogenesis of metastatic adenocarcinomas, particularly when the primary site is unknown, is not completely understood and can give a varied radiological presentation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lumbar Vertebrae / pathology. Lumbar Vertebrae / surgery. Spinal Neoplasms / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 21162500.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Wang L, Vuolo M, Suhrland MJ, Schlesinger K: HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol; 2006 May-Jun;50(3):257-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
  • OBJECTIVE: To investigate immunohistochemical staining of hepatocyte paraffin-1 (HepPar1), alpha-fetoprotein (AFP), polyclonal carcinoembryonic antigen (pCEA), monoclonal CEA (mCEA), MOC-31 and CD10 for differential diagnosis of hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) on fine needle aspiration biopsy (FNAB).
  • [MeSH-major] Adenocarcinoma / secondary. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780018.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


29. García J, Campos J, Abdulkader I, León L, López R: [Collision tumor consisting in a metastatic adenocarcinoma and follicular lymphoma in the same lymph node. Report of one case]. Rev Med Chil; 2009 Jan;137(1):83-7
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Collision tumor consisting in a metastatic adenocarcinoma and follicular lymphoma in the same lymph node. Report of one case].
  • [Transliterated title] Tumor de colisión. Metástasis de adenocarcinoma y linfoma folicular en un mismo ganglio linfático.
  • We report a 52 year-old woman with a collision tumor consisting of metastatic adenocarcinoma and follicular lymphoma present in the same lymph node, excised from the left supraclavicular space.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Lymphoma, Follicular / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19399326.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


30. Choi GY, Kim A, Kim CN, Yoon SJ, Jung SH, Ko BS, Yang HY, John BM, Kim SH, Nam HJ, Go H: [A case of subphrenic abscess with ileal fistula caused by metastatic adenocarcinoma of unknown origin]. Korean J Gastroenterol; 2005 Dec;46(6):471-4
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of subphrenic abscess with ileal fistula caused by metastatic adenocarcinoma of unknown origin].
  • Reported cases of intestinal fistula caused by adenocarcinoma were complicated by direct invasion.
  • In this report, a 70-year-old male had a subphrenic abscess with intestinal fistula and the cause was a metastatic adenocarcinoma of unknown origin.
  • Invasion of the ileum by metastatic adenocarcinoma was diagnosed by the histologic examination of surgical specimen.
  • [MeSH-major] Adenocarcinoma / secondary. Ileal Diseases / etiology. Ileal Neoplasms / secondary. Intestinal Fistula / etiology. Neoplasms, Unknown Primary. Subphrenic Abscess / etiology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371722.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


31. Sharma A, Raina V, Lokeshwar N, Deo SV, Shukla NK, Mohanti BK: Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. Indian J Cancer; 2006 Jan-Mar;43(1):16-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.
  • BACKGROUND: Unresectable and metastatic gastric cancers carry a poor and dismal prognosis.
  • AIMS: To evaluate safety and efficacy of low-dose cisplatin, etoposide and paclitaxel (CEP) based combination chemotherapy in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction.
  • Twenty-nine had metastatic/inoperable disease and four patients had recurrent disease.
  • Liver was the commonest metastatic site seen in 15 patients.
  • CONCLUSION: Combination of low-dose CEP shows good clinical response and an acceptable toxicity profile in advanced or metastatic adenocarcinoma of gastric/gastroesophageal cancers.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction / drug effects. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763357.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Chen JL, Huang TW, Hsu PS, Chao-Yang, Tsai CS: Cardiac tamponade as the initial manifestation of metastatic adenocarcinoma from the colon: a case report. Heart Surg Forum; 2007;10(4):E329-30
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade as the initial manifestation of metastatic adenocarcinoma from the colon: a case report.
  • Metastatic cardiac malignancies mainly come from the lung, breast, and the lymphoreticular system by direct invasion or hematogenous or lymphatic spread.
  • We report an unusual case of malignant pericardial effusion caused by metastatic adenocarcinoma of colon.
  • [MeSH-major] Adenocarcinoma / complications. Cardiac Tamponade / etiology. Colonic Neoplasms / pathology. Heart Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650460.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol; 2008 Nov;19(11):1882-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
  • PATIENTS AND METHODS: Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks.
  • Patients had a median age of 60 years (range 29-76) and most (93%) of them had metastatic disease.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669868.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Jariengprasert C, Laothamatas J, Janwityanujit T, Phudhichareonrat S: Bilateral sudden sensorineural hearing loss as a presentation of metastatic adenocarcinoma of unknown primary mimicking cerebellopontine angle tumor on the magnetic resonance image. Am J Otolaryngol; 2006 Mar-Apr;27(2):143-5
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sudden sensorineural hearing loss as a presentation of metastatic adenocarcinoma of unknown primary mimicking cerebellopontine angle tumor on the magnetic resonance image.
  • Surgical biopsy and histopathologic finding identified masses secondary to direct invasion of adenocarcinoma of gastrointestinal origin.
  • Many investigations could not discover the primary site of the metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cerebellar Neoplasms / diagnosis. Cerebellopontine Angle / pathology. Hearing Loss, Sensorineural / diagnosis. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500481.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Mahalingam M, Nguyen LP, Richards JE, Muzikansky A, Hoang MP: The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol; 2010 May;23(5):713-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin.
  • Often the distinction of primary adnexal carcinoma from metastatic adenocarcinoma to skin from breast, lung, and other sites can be a diagnostic dilemma.
  • Current markers purportedly of utility as diagnostic adjuncts include p63 and D2-40; however, their expression has been demonstrated in 11-22% and 5% of metastatic cutaneous metastases, respectively.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190734.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Intermediate Filament Proteins; 0 / Keratin-15; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / S100 Calcium Binding Protein G; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / monoclonal antibody D2-40
  •  go-up   go-down


36. Blanke CD, Chansky K, Christman KL, Hundahl SA, Issell BF, Van Veldhuizen PJ Jr, Budd GT, Abbruzzese JL, Macdonald JS: S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. Am J Clin Oncol; 2010 Apr;33(2):117-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
  • METHODS: Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. TRIMETREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2000 May;58(4):273-9 [10838491.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):729-33 [18083691.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):87-91 [11863117.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):92-4 [11865815.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Cancer Res. 1982 May;42(5):1696-702 [6461409.001]
  • [Cites] Biochem Pharmacol. 1984 May 15;33(10):1697-9 [6233981.001]
  • [Cites] NCI Monogr. 1987;(5):105-9 [2963228.001]
  • [Cites] NCI Monogr. 1987;(5):99-104 [2963231.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):5029-35 [2970294.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):124-30 [2909752.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Jun;25(6):977-82 [2526736.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(5):314-20 [2758561.001]
  • [Cites] Cancer Res. 1989 Oct 15;49(20):5586-90 [2477146.001]
  • [Cites] Anticancer Res. 1989 Jul-Aug;9(4):1025-6 [2817784.001]
  • [Cites] Invest New Drugs. 1990 May;8(2):159-66 [2143500.001]
  • [Cites] J Natl Cancer Inst. 1992 Jul 1;84(13):1033-8 [1376779.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):695-700 [7512128.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):915-20 [9060528.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):4001-3 [11099333.001]
  • (PMID = 19770625.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46136; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA032102-32; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA52757; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; UPN4ITI8T4 / Trimetrexate
  • [Other-IDs] NLM/ NIHMS244743; NLM/ PMC2967385
  •  go-up   go-down


37. Lee DH, Han JY, Yu SY, Kim HY, Nam BH, Hong EK, Kim HT, Lee JS: The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol; 2006 Nov;1(9):965-71
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.
  • PURPOSE: This prospective trial was conducted to evaluate the role of gefitinib in never-smokers with advanced or metastatic adenocarcinoma of the lung.
  • PATIENTS AND METHODS: The main inclusion criteria were stage IIIB/IV adenocarcinoma of the lung and status as a lifetime never-smoker.
  • CONCLUSION: Gefitinib showed very promising antitumor activity and survival outcome in Korean never-smokers with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Neoplasm Invasiveness / pathology. Quinazolines / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409980.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


38. Gutmann EJ, Suriawinata A, Gordon S: Barrett's esophagus with high-grade dysplasia simulating metastatic adenocarcinoma in a fine needle aspiration biopsy. Diagn Cytopathol; 2006 Jul;34(7):507-10
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus with high-grade dysplasia simulating metastatic adenocarcinoma in a fine needle aspiration biopsy.
  • The aspirate contained markedly atypical clustered large cells that displayed prominent nucleoli and mitoses, as well as lymphoid cells, suggestive of adenocarcinoma metastatic to a lymph node.
  • [MeSH-major] Adenocarcinoma / secondary. Barrett Esophagus / pathology. Biopsy, Fine-Needle. Esophageal Neoplasms / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16783781.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Jan IS, Chung PF, Weng MH, Huang MS, Lee YT, Kuo SH: Utility of thyroid transcription factor-1 expression in the differential diagnosis of metastatic adenocarcinoma of serous effusion specimens prepared using the cell transfer technique. J Formos Med Assoc; 2006 Sep;105(9):695-700
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of thyroid transcription factor-1 expression in the differential diagnosis of metastatic adenocarcinoma of serous effusion specimens prepared using the cell transfer technique.
  • BACKGROUND/PURPOSE: Pulmonary adenocarcinoma is a common malignancy of the pleural cavity.
  • The goal of this study was to investigate the pulmonary origin of metastatic adenocarcinoma by evaluating the immunocytochemical reactivity to thyroid transcription factor-1 (TTF-1) of slides of serous effusion specimens prepared by the cell transfer technique.
  • METHODS: In 2001, a total of 76 archived serous effusion specimens containing adenocarcinoma from patients were used in this study.
  • The primary site of metastatic adenocarcinoma was determined by a review of the medical records.
  • Lung adenocarcinoma showed TTF-1 positivity in 82% of specimens, and all other adenocarcinomas had negative TTF-1 staining results.
  • CONCLUSION: This study demonstrated that TTF-1 immunostaining in serous effusion specimens prepared using the cell transfer technique is a sensitive and highly specific marker for metastatic lung adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959616.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


40. Yeh KH, Yeh SH, Wan JP, Shen YC, Cheng AL: Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anticancer Drugs; 2005 Aug;16(7):739-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
  • A 61-year-old never-smoker female suffered from adenocarcinoma of the lung with chest wall invasion and peri-adrenal lymph node metastases.
  • After palliative resection of all clinically detectable primary and metastatic adenocarcinoma, she received cisplatin and gemcitabine combination chemotherapy for a total of 3 cycles.
  • New metastatic lesions were found in spleen and para-aortic lymph nodes.
  • Our patient supports the proposition that somatic mutation L858R in exon 21 of the EGFR gene accounts for complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027522.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib
  •  go-up   go-down


41. Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikcevich DA, North Central Cancer Treatment Group: Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol; 2006 Apr;17(4):652-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
  • BACKGROUND: Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction.
  • CONCLUSIONS: The regimen docetaxel and capecitabine shows activity in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497828.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / CA-63844; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr, North Central Cancer Treatment Group: Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol; 2006 Jan;17(1):29-34
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
  • We therefore undertook this phase II study to test this first-line combination in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia.
  • CONCLUSIONS: Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303863.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35119; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Castillo-Sang M, Slam K, Gociman B, Durham SJ, Booth R: Endometrial adenocarcinoma metastatic to the right ventricle: a case report and review of the literature. Cardiovasc Pathol; 2009 May-Jun;18(3):178-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma metastatic to the right ventricle: a case report and review of the literature.
  • BACKGROUND: Endometrial adenocarcinoma of any histologic type rarely metastasizes to the heart.
  • Her past medical history was significant for a resected Stage IC endometrial adenocarcinoma endometrioid type 15 months prior.
  • The tumor was found to be a poorly differentiated (Grade 3) endometrial adenocarcinoma invading over half the myometrium.
  • Subsequent endocardial biopsy showed a poorly differentiated, Grade 3, endometrial adenocarcinoma of endometrioid histologic type.
  • CONCLUSION: Management of metastatic adenocarcinoma to the heart is not well established due to the rarity of this lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402828.001).
  • [ISSN] 1879-1336
  • [Journal-full-title] Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
  • [ISO-abbreviation] Cardiovasc. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


44. Alfonso M, Adochiles L, Hendrickson VM, Carver DK, Rodriguez GC, Barnes HJ: Metastatic adenocarcinoma in the lungs of older laying hens. Avian Dis; 2005 Sep;49(3):430-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma in the lungs of older laying hens.
  • Grossly visible metastatic tumors in the lungs of a few birds prompted collection of lungs from 228 affected hens for histologic examination.
  • Metastatic adenocarcinomas were identified histologically in the lungs of 42 of the 228 hens (18.4%).
  • Metastatic foci showing expansive or invasive growth were identified.
  • These findings indicate that vascular spread of adenocarcinomas is more common than previously thought in chickens, and the lungs are often involved with metastatic tumors, primarily from the reproductive tract.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / veterinary. Aging / physiology. Chickens. Lung Neoplasms / secondary. Lung Neoplasms / veterinary. Oviposition

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16252501.001).
  • [ISSN] 0005-2086
  • [Journal-full-title] Avian diseases
  • [ISO-abbreviation] Avian Dis.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01 CN005114
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


45. Hamer OW, Flint J, Ryan CF, Manos D, Müller NL: Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix. Br J Radiol; 2008 Aug;81(968):e201-3
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix.
  • Here, we describe an uncommon case of endobronchial metastasis of adenocarcinoma of the cervix causing mucoid impaction owing to mucous production by the tumour cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Bronchial Neoplasms / secondary. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628324.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Martin JT, Alkhoury F, Helton S, Fiedler P, Sakharova O, Yood S: Metastatic adenocarcinoma within a functioning adrenal adenoma: a case report. Cases J; 2009;2:7965

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma within a functioning adrenal adenoma: a case report.
  • She had recently been diagnosed with lung adenocarcinoma.
  • Pathologic findings revealed a 5 cm adrenal adenoma with a metastatic adenocarcinoma deposit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1990 Mar;43(3):154-6 [2314102.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;416(2):153-7 [2512743.001]
  • [Cites] Arch Pathol Lab Med. 1988 Mar;112(3):286-9 [2830864.001]
  • [Cites] AJR Am J Roentgenol. 1996 Oct;167(4):891-2 [8819376.001]
  • [Cites] J Surg Oncol. 1998 Sep;69(1):54-7 [9762893.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jun;132(6):1016-20 [18517262.001]
  • [Cites] J Pathol Bacteriol. 1963 Oct;86:541-3 [14068966.001]
  • [Cites] World J Surg Oncol. 2004;2:37 [15541184.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 May;27(5):753-6 [15848309.001]
  • [Cites] Pathol Int. 2005 Sep;55(9):574-9 [16143033.001]
  • [Cites] Int J Surg Pathol. 2003 Apr;11(2):127-35 [12754635.001]
  • (PMID = 19830028.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740135
  •  go-up   go-down


47. André T, Wislez M, Goncalves A, de La Motte Rouge T, Blay JY, Massard C, Bay JO, comité de rédaction du Bulletin du Cancer: [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer]. Bull Cancer; 2010 Dec;97(12):1551-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Suite aux communications faites au congrès de l'American Society of Clinical Oncology 2010, qu'est ce qui va changer nos pratiques ? Le point de vue du comité de rédaction du Bulletin du cancer.
  • The identification of the gene of fusion EML4-ALK in lung adenocarcinoma, and its inhibition by the crizotinib, constitute a considerable progress for 5% of patients with this disease.
  • In metastatic adenocarcinoma of the pancreas, there is finally an alternative to gemcitabine with the Folfirinox regimen, with an improvement of overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220230.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


48. Adams G, Mitchell A, Ravichandran R, Beer TM, Garzotto M: Metastatic adenocarcinoma of prostate in a healing sternotomy site. Urology; 2006 Jul;68(1):204.e13-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of prostate in a healing sternotomy site.
  • Metastatic prostate cancer has a strong predilection for osseous sites, where the disease spreads in 80% of advanced cases.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Prostatic Neoplasms / pathology. Sternum / surgery. Wound Healing

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808964.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol; 2007 Jan;20(1):120-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
  • In order to evaluate the potential role of such a treatment in esophageal cancers, HER-2 amplification and overexpression was investigated in primary and metastatic cancers of the esophagus.
  • We conclude that esophageal adenocarcinomas belong to those cancer types with relevant frequency high-level HER-2 gene amplification clinical trials or individual case studies investigating the response of metastatic HER-2-positive esophageal cancers to Herceptin((R)) should be undertaken.
  • The strong concordance of the HER-2 status in primary and metastatic cancers argues for a possible response of metastases from patients with HER-2-positive primary tumors to Herceptin.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Gene Amplification. Gene Expression Regulation, Neoplastic. Genes, erbB-2. Receptor, ErbB-2 / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143264.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


50. Hata A, Nanjo S, Otsuka K, Kida Y, Higashi Y, Kaji R, Fujita S, Katakami N: [Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies]. Gan To Kagaku Ryoho; 2009 May;36(5):807-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies].
  • She was diagnosed as having lung adenocarcinoma with multiple metastases (cT4N0M1, stage IV, mucinous BAC)in June, 2004.
  • She was diagnosed as having lung adenocarcinoma with multiple metastases(cT4N3M1, stage IV)in October, 2004.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461182.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


51. Ivan D, Nash JW, Prieto VG, Calonje E, Lyle S, Diwan AH, Lazar AJ: Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol; 2007 Jun;34(6):474-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin.
  • Others and we have shown the value of p63 in distinguishing primary adnexal tumors from visceral adenocarcinomas metastatic to skin.
  • Twenty visceral metastatic adenocarcinomas to the skin and 7 primary mucinous carcinomas with cutaneous or visceral origin were compared.
  • With one exception, primary or metastatic mucinous carcinomas did not express p63.
  • Analysis of p63 expression may assist in the differential diagnosis of primary adnexal carcinomas versus metastatic visceral adenocarcinomas to the skin.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Skin Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2008 Jul;35(7):692-3 [18312438.001]
  • (PMID = 17518775.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


52. Buddula A: A case report of metastatic adenocarcinoma of the gingiva. J Indian Soc Periodontol; 2009 Jan;13(1):55-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of metastatic adenocarcinoma of the gingiva.
  • Scant literature is available reporting enlargement of gingiva due the metastasis of adenocarcinoma from lung.
  • The case report presents a unique case of an adenocarcinoma in the lung metastasizing to the buccal and lingual interdental papillae of teeth numbering 34 and 35.
  • A 72-year-old female was referred to the Mayo Clinic with a recent diagnosis of metastatic stage IV adenocarcinoma of the left lung presented with an abnormal mass located on the left posterior buccal keratinized tissue adjacent to teeth numbering 34-35.
  • The tumor cells were positive for CK7 and TTF-1, and weakly positive for p63 suggesting a diagnosis of adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Dent J. 1949 Mar 4;86(5):109-11 [18113569.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1965 Sep;20:350-62 [14342927.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):831-5 [15209637.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1961 Aug;14:897-905 [13691275.001]
  • [Cites] J Periodontol. 1976 Jun;47(6):358-60 [1064724.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1969 Dec;28(6):859-61 [5260657.001]
  • [Cites] Acta Pathol Microbiol Scand. 1963;57:361-74 [14064805.001]
  • (PMID = 20376244.001).
  • [ISSN] 0975-1580
  • [Journal-full-title] Journal of Indian Society of Periodontology
  • [ISO-abbreviation] J Indian Soc Periodontol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2846678
  • [Keywords] NOTNLM ; Adenocarcinoma / gingival enlargement / metastasis
  •  go-up   go-down


53. Sun C, Jackson CS, Reeves M, Rendon S: Metastatic adenocarcinoma of the gastric pouch 5 years after Roux-en-Y gastric bypass. Obes Surg; 2008 Mar;18(3):345-8
MedlinePlus Health Information. consumer health - Weight Loss Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the gastric pouch 5 years after Roux-en-Y gastric bypass.
  • At the time of detection, the cancer was already metastatic.
  • This case represents the first reported metastatic gastric adenocarcinoma arising from the gastric pouch following RYGBP.
  • [MeSH-major] Adenocarcinoma / secondary. Gastric Bypass. Liver Neoplasms / secondary. Obesity, Morbid / surgery. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obes Surg. 2003 Oct;13(5):800-2 [14627482.001]
  • [Cites] Radiol Med. 2004 May-Jun;107(5-6):515-23 [15195014.001]
  • [Cites] Obes Surg. 2004 Apr;14(4):559-61 [15130239.001]
  • [Cites] Obes Surg. 2004 Oct;14(9):1157-64 [15527627.001]
  • [Cites] Obes Surg. 2006 Jul;16(7):928-31 [16839496.001]
  • [Cites] Obes Surg. 2006 Jul;16(7):935-8 [16839498.001]
  • [Cites] J Clin Gastroenterol. 1991 Apr;13(2):191-4 [1843447.001]
  • [Cites] Obes Surg. 2002 Oct;12(5):634-8 [12448383.001]
  • [Cites] Obes Surg. 2005 Mar;15(3):423-7 [15826480.001]
  • [Cites] G Chir. 2000 Apr;21(4):172-6 [10812773.001]
  • [Cites] Obes Surg. 2002 Feb;12(1):118-20 [11868287.001]
  • [Cites] Ann Surg. 1995 Sep;222(3):339-50; discussion 350-2 [7677463.001]
  • [Cites] JSLS. 2004 Oct-Dec;8(4):372-5 [15554284.001]
  • [Cites] Aust N Z J Surg. 1997 Aug;67(8):580-2 [9287934.001]
  • [Cites] Ann Surg. 1977 Oct;186(4):500-9 [907395.001]
  • [Cites] Obes Surg. 2005 Sep;15(8):1215-7 [16197800.001]
  • [Cites] Obes Surg. 2003 Feb;13(1):136-7 [12630629.001]
  • [Cites] Obes Surg. 1998 Oct;8(5):505-16 [9819081.001]
  • [Cites] Clin Ther. 1996 Nov-Dec;18(6):1006-35; discussion 1005 [9001821.001]
  • [Cites] Curr Gastroenterol Rep. 2005 Aug;7(4):321-8 [16042918.001]
  • [Cites] Obes Surg. 2002 Oct;12(5):693-4 [12448394.001]
  • [Cites] Surg Endosc. 2002 May;16(5):736-44 [11997813.001]
  • (PMID = 18219541.001).
  • [ISSN] 0960-8923
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Sheridan T, Herawi M, Epstein JI, Illei PB: The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol; 2007 Sep;31(9):1351-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
  • BACKGROUND: Adenocarcinoma of the prostate can present as metastatic carcinoma with no known primary.
  • Owing to its apparent specificity, prostein may be a good marker to demonstrate prostatic origin in metastatic prostate cancer.
  • The tissue microarray contains 78 cases of metastatic prostatic adenocarcinoma, 20 cases of primary prostatic adenocarcinoma, and 20 cases of benign prostate tissue from the peripheral zone as well as samples of benign brain, pancreas, kidney, thyroid, testis, skeletal muscle, and fibroconnective tissue.
  • RESULTS: Similar staining (intensity and extent) was identified for both markers in the majority of metastatic tumors (11 distant sites, 42 pelvic lymph nodes), in all 20 primary tumors and in all benign prostate and nonprostate tissues.
  • In summary, 67 of the 69 cases (97%) of metastatic prostate carcinomas were PSA positive, whereas 68 of the 69 cases showed at least focal weak reactivity for P501S (99%).
  • The large majority of metastatic prostatic adenocarcinomas are P501S positive (99%).
  • A small subset of metastatic prostatic adenocarcinoma shows significant differences in staining intensity and extent for PSA and P501S and, therefore, combined use of these markers may result in increased sensitivity for detecting prostatic origin.
  • [MeSH-major] Adenocarcinoma / diagnosis. Membrane Proteins / analysis. Neoplasms, Unknown Primary / diagnosis. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721190.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / prostein; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


55. Renshaw AA, Haja J, Wilbur DC, Miller TR, Cytology Committee, College of American Pathologists: Fine-needle aspirates of adenocarcinoma/metastatic carcinoma that resemble hepatocellular carcinoma: correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program. Arch Pathol Lab Med; 2005 Oct;129(10):1217-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspirates of adenocarcinoma/metastatic carcinoma that resemble hepatocellular carcinoma: correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program.
  • CONTEXT: The cytologic features of adenocarcinoma/ metastatic carcinoma in liver fine-needle aspirates are well described.
  • We review the cytologic findings from 16 aspirates of adenocarcinoma/metastatic carcinoma that were frequently misclassified as hepatocellular carcinomas and compare them with 17 cases that were rarely misclassified.
  • OBJECTIVE: To compare the cytologic features of adenocarcinoma/metastatic carcinoma in fine-needle aspiration specimens of the liver that were frequently misclassified as hepatocellular carcinoma with those of aspirates that were rarely misclassified.
  • DESIGN: We reviewed a total of 1712 interpretations from 33 different cases of adenocarcinoma/metastatic carcinoma tumor in liver fine-needle aspiration specimens in the College of American Pathologists Nongynecologic Cytology Program and correlated the cytologic features with performance in the program.
  • CONCLUSION: Cases of adenocarcinoma/metastatic carcinoma with moderate amounts of granular cytoplasm and round nuclei with even chromatin are frequently misclassified as hepatocellular carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Biopsy, Fine-Needle / methods. Carcinoma, Hepatocellular / secondary. Clinical Competence. Liver Neoplasms / pathology. Pathology, Surgical / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196506.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Gökçe M, Korkmaz L, Oz D, Orem C, Kiris A, Ahmetoğlu A: Metastatic adenocarcinoma in the right atrium and secondary Budd-Chiari syndrome (a case report). Int J Cardiol; 2009 Feb 6;132(1):e1-4
Genetic Alliance. consumer health - Budd-Chiari Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma in the right atrium and secondary Budd-Chiari syndrome (a case report).
  • Metastatic cardiac tumors (MCT) are much more common than the primary cardiac tumors.
  • We report an unusual case of Budd-Chiari syndrome which was associated with metastatic right atrial adenocarcinoma with unknown origin in a 60-year-old woman.
  • [MeSH-major] Adenocarcinoma / secondary. Budd-Chiari Syndrome / etiology. Heart Neoplasms / secondary. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023895.001).
  • [ISSN] 1874-1754
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Compérat E, Zhang F, Perrotin C, Molina T, Magdeleinat P, Marmey B, Régnard JF, Audouin J, Camilleri-Broët S: Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol; 2005 Oct;18(10):1371-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin.
  • Two different clones of antibodies (8G7G1/1 from Dako, SPT24 from Novocastra) raised against TTF-1 were used on 56 lung-metastatic malignant tumors, 41 from colorectal origin.
  • Three of the four positive cases displayed similar nuclear staining in primary and/or other extrathoracic metastatic sites as well as four of 90 (5%) primary colorectal adenocarcinomas, ruling out the role of lung microenvironment.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Antibodies. Colorectal Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Nuclear Proteins / immunology. Transcription Factors / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861215.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


58. Spyropoulou D, Vassiliou V, Tzelepi V, Kardari M, Tsamandas AC, Kardamakis D: Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature. J Gastrointest Cancer; 2007;38(2-4):95-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature.
  • AIM: To report a rare case of metastasis from an adenocarcinoma of the ampulla of Vater to the parotid gland.
  • PATIENTS AND METHODS: In February 2004, a 61-year-old male underwent Whipple surgery due to a grade II adenocarcinoma of the ampulla of Vater (stage IB:pT2N0M0).
  • Two years post surgery, an abdominal computed tomography (CT) revealed metastatic hepatic lesions.
  • Fine needle aspiration showed that the infiltrating mass was due to an adenocarcinoma of the ampulla of Vater.
  • CONCLUSIONS: Metastasis of adenocarcinoma of the ampulla of Vater to the parotid gland has not to our knowledge been previously reported.
  • [MeSH-major] Adenocarcinoma / secondary. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Parotid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Arch Surg. 1963 Nov;87:757-64 [14058839.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2005 Feb;122(1):18-20 [15851941.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Dec;135(6):844-8 [17141071.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):190-2 [3971828.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Otolaryngol Pol. 2005;59(4):547-52 [16273860.001]
  • [Cites] J Surg Oncol. 1976;8(2):183-90 [1263521.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Feb;8(2):139-44 [8723418.001]
  • [Cites] Diagn Cytopathol. 2006 Aug;34(8):580-4 [16850487.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):286-90 [17326125.001]
  • [Cites] Int J Urol. 2004 Oct;11(10):894-6 [15479296.001]
  • [Cites] Australas Radiol. 2004 Mar;48(1):88-92 [15027931.001]
  • [Cites] Acta Otorrinolaringol Esp. 2006 Jan;57(1):47-50 [16503033.001]
  • [Cites] Clin Transl Oncol. 2007 Apr;9(4):264-5 [17462982.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1070-5 [12782825.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2007;69(1):51-6 [17085953.001]
  • (PMID = 19016351.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Veshapidze N, Chigogidze T, Managadze L, Gabunia N, Kotrikadze N: Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy. Georgian Med News; 2007 Dec;(153):11-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy.
  • The changes of electrophoretic mobility of erythrocytes in the practically healthy men and in men with metastatic prostate cancer before and after castration were studied.
  • Investigation revealed, that the level of electrophoretic mobility of erythrocytes was decreased in the blood of metastatic prostate cancer patients (before castration), as compared with control group and with post operational period data.
  • It was found, that during the malignant adenocarcinoma of prostate (before and after surgery) pathological changes in organism effect erythrocytes superficial membranes and alter their electrical and structural parameters.
  • Probably, that is one of the reasons of considerable decrease of erythrocytes electrophoretic mobility in patients with metastatic prostate adenocarcinoma (before castration).
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Erythrocytes / metabolism. Erythrocytes / ultrastructure. Orchiectomy / methods. Postoperative Care. Preoperative Care. Prostatic Neoplasms / secondary. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250488.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


60. Fang F, Yang L, Su XL, He Q, Liu DG, Lin FR, Ma ZZ: [Determining the primary site of metastatic adenocarcinoma in serous fluid: a cytological study]. Zhonghua Bing Li Xue Za Zhi; 2005 Oct;34(10):641-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Determining the primary site of metastatic adenocarcinoma in serous fluid: a cytological study].
  • OBJECTIVE: To explore cytological parameters that may identify the primary sites of metastatic adenocarcinomas in serous fluid.
  • METHODS: Serous fluid specimens from 89 cases of metastatic adenocarcinomas (40 metastatic adenocarcinomas of lung, 6 metastatic adenocarcinomas of breast, 21 metastatic ovary adenocarcinomas, 22 metastatic gastrointestinal and pancreatic adenocarcinomas) were studied by using multiple morphologic parameters.
  • RESULTS: Metastatic adenocarcinomas of different primary sites displayed certain different morphologic features, including the total amount of tumor cells, size of clusters, ratio of clusters over single cells, configuration of tumor clusters and the background of the smear.
  • Cell clusters of small to medium sizes represented 95% and 100% in the metastatic adenocarcinomas of lung and breast, respectively.
  • Most of the ovarian metastatic adenocarcinomas (85.7%) presented some large cell clusters and larger amount of cells, whereas certain metastatic gastrointestinal and pancreatic adenocarcinomas (45.5%) presented smaller number of cells and predominantly to be single cell in distribution (40.9%).
  • Psammoma bodies were found in metastatic adenocarcinomas of lung and ovary.
  • SPB and TTF-1 expression supported the diagnosis of adenocarcinoma of pulmonary origin.
  • Although CA199 was seen in all groups of metastatic adenocarcinomas, nevertheless, its appearance in tumor cells in ascitic fluid specimens supported gastrointestinal and pancreatic origins.
  • CONCLUSION: Morpho-logic features of the cytological smear, immunohistochemical staining and clinical history are equally important in determining the primary sites of metastatic adenocarcinomas in serous fluid.
  • [MeSH-major] Adenocarcinoma / secondary. Ascitic Fluid / pathology. Lung Neoplasms / pathology. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536276.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Nuclear Proteins; 0 / Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


61. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res; 2005 Apr 15;11(8):3032-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
  • PURPOSE: A subset of patients with adenocarcinoma of the lung who had never smoked cigarettes showed excellent tumor responses to gefitinib therapy.
  • EXPERIMENTAL DESIGN: Eligible patients had no smoking history, stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate organ functions.
  • CONCLUSIONS: Gefitinib showed very dramatic antitumor activity, even in the brain, with unprecedented survival outcome in never-smoker adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


62. Kong A, Koukourou A, Boyd M, Crowe G: Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis. J Clin Neurosci; 2006 Nov;13(9):955-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis.
  • Subsequent histopathology demonstrated metastatic papillary adenocarcinoma and immunohistochemical studies revealed the origin to be that of primary lung carcinoma.
  • In summary, the 'target sign' is a non-specific radiologic finding but most commonly indicates cerebral tuberculoma or metastatic adenocarcinoma in the appropriate clinical context.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Diagnostic Errors / prevention & control. Lung Neoplasms / pathology. Tuberculosis, Central Nervous System / diagnosis

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085301.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


63. Ruparelia N, Ahmadi H, Cobiella C: Metastatic adenocarcinoma of the colon presenting as a monarthritis of the hip in a young patient. World J Surg Oncol; 2006;4:95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the colon presenting as a monarthritis of the hip in a young patient.
  • BACKGROUND: Malignant arthritis is a rare manifestation of metastatic disease.
  • Computed tomography and bone scan confirmed widespread metastatic disease from a primary colonic adenocarcinoma.
  • CONCLUSION: The metastatic spread of cancer to the joint and the synovium is one of the rarest manifestations of malignant disease and has not been previously reported as the presenting symptom of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):939-51 [4016686.001]
  • [Cites] JAMA. 1978 Mar 13;239(11):1070-1 [628056.001]
  • [Cites] Q J Med. 1984 Winter;53(209):135-43 [6709822.001]
  • [Cites] Arthritis Rheum. 1980 Jan;23(1):95-100 [7352950.001]
  • [Cites] Arthritis Rheum. 1975 Mar-Apr;18(2):107-10 [1131279.001]
  • [Cites] Am Surg. 1994 Aug;60(8):607-12 [8030817.001]
  • [Cites] Science. 1993 May 7;260(5109):751-2 [8484115.001]
  • [Cites] J Rheumatol. 1995 May;22(5):973-5 [8587092.001]
  • [Cites] Australas Radiol. 2000 Nov;44(4):474-7 [11103553.001]
  • [Cites] J Rheumatol. 1980 Jan-Feb;7(1):98-104 [7354476.001]
  • (PMID = 17169149.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1716166
  •  go-up   go-down


64. Kadikoylu G, Barutca S, Tataroglu C, Kafkas S, Erpek H, Meydan N, Yavasoglu I, Bolaman Z: Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman. Transfus Apher Sci; 2010 Feb;42(1):39-42
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman.
  • Thrombotic microangiopathy occurs in 5-10% of patients with mucin-producing disseminated adenocarcinoma.
  • Signet ring cell adenocarcinoma stained with cytokeratin 7 and mucicarmine was seen on ovaries and bone marrow, after the pathological examination.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Bone Marrow Neoplasms / secondary. Carcinoma, Signet Ring Cell / secondary. Neoplasms, Unknown Primary / complications. Ovarian Neoplasms / secondary. Purpura, Thrombotic Thrombocytopenic / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19926523.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


65. Amanie J, Pearcey RG, Honore L, Sloboda R: Metastatic adenocarcinoma of the cervix in a delivery-induced traumatic lower vaginal tear. Gynecol Oncol; 2005 Mar;96(3):857-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the cervix in a delivery-induced traumatic lower vaginal tear.
  • [MeSH-major] Adenocarcinoma / secondary. Uterine Cervical Neoplasms / pathology. Vagina / injuries. Vaginal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721438.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Ghumro MY, Drew L, Tariq SM: An unusual presentation of metastatic adenocarcinoma of lung: a case report. Cases J; 2009;2:9401

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic adenocarcinoma of lung: a case report.
  • We report an unusual patient with primary adenocarcinoma of lung causing malignant pleural and pericardial effusions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 2006 Oct;82(972):642-8 [17068274.001]
  • [Cites] BMJ. 2009;339:b3527 [19773328.001]
  • [Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]
  • (PMID = 20084189.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2807440
  •  go-up   go-down


67. Carballo M, Maish MS, Jaroszewski DE, Yetasook A, Bauer K, Cameron RB, Carmack Holmes E: Video-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative. Surg Endosc; 2009 Sep;23(9):1947-54
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative.
  • This study reviews metastatic resections in primary adenocarcinoma patients, using both thoracotomy and VATS.
  • METHODS: A retrospective review of primary adenocarcinoma patients who underwent resection of pulmonary metastases from 1990 to 2006 was carried out.
  • RESULTS: In a total of 42 (16 male, 26 female; median age 58.5 years) primary adenocarcinoma patients, 21 patients underwent first pulmonary metastatic resection using VATS (7 male, 14 female; median age 57 years) and 21 using thoracotomy (9 male, 12 female; median age 59 years).
  • In cases of primary adenocarcinoma, VATS showed no increase in number of thoracic recurrences, and comparable RFS.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Jan;24(1):27-30; discussion 30-1 [10594199.001]
  • [Cites] Chest. 2001 Apr;119(4):1069-72 [11296171.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Jun;19(6):908-13 [11404151.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):906-12 [12062285.001]
  • [Cites] Eur Respir J Suppl. 2003 Jan;39:57s-66s [12572703.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Mar;23(3):397-402 [12614813.001]
  • [Cites] Surg Oncol. 2003 Nov;12(3):195-200 [12957623.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1194-9 [15464469.001]
  • [Cites] Ann Thorac Surg. 1984 Oct;38(4):323-30 [6486949.001]
  • [Cites] Chest. 1986 Jan;89(1):109-12 [3940769.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Dec;106(6):1111-7 [8246547.001]
  • [Cites] Ann Thorac Surg. 1993 Dec;56(6):1248-52; discussion 1252-3 [8267420.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49 [9011700.001]
  • [Cites] Ann Thorac Surg. 1998 Apr;65(4):909-12 [9564899.001]
  • [Cites] Int J Clin Oncol. 2005 Apr;10(2):81-5 [15864692.001]
  • [Cites] Surg Endosc. 2004 Nov;18(11):1657-62 [16237587.001]
  • [Cites] J Zhejiang Univ Sci B. 2006 Feb;7(2):118-28 [16421967.001]
  • [Cites] J Nippon Med Sch. 2006 Jun;73(3):116-21 [16790977.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Sep;132(3):507-12 [16935102.001]
  • [Cites] Surg Endosc. 2007 Oct;21(10):1883-6 [17310297.001]
  • (PMID = 19116749.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2730451
  •  go-up   go-down


68. Shidham VB, Komorowski RA, Machhi JK: Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary. Diagn Pathol; 2006;1:34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary.
  • BACKGROUND: The differential diagnosis of metastatic mammary adenocarcinoma and adenocarcinomas from other primary sites can be challenging, particularly in tumors that are poorly differentiated and negative for Estrogen/Progesterone receptors (ER/PR).
  • With progression of disease, Androgen receptors (AR) are preserved with higher frequency than ER/PR in metastatic mammary carcinoma.
  • This study was undertaken to evaluate the diagnostic significance of AR expression in adenocarcinoma of breast and other morphologically similar adenocarcinomas.
  • DESIGN: Formalin-fixed paraffin-embedded tissue sections of 113 primary adenocarcinoma of various sites [breast (34, all females), lung (23, M- 6, F-17), colon (9, M-2, F-7), stomach (6, M-4, F-2), liver and bile duct (11, M-5, F-6), pancreas (7, M-2, F-5), ovary (10), endometrium (7), and cervix (6)] were immunostained with monoclonal antibody for AR.
  • RESULTS: 56% (19/34) mammary carcinoma and 20% (2/10) adenocarcinoma of ovary were positive for AR.
  • If metastatic tumor with unknown primary in a female is AR positive, breast and ovary are the most likely primary sites.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1995 Jan-Feb;45(1):8-30 [7528632.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1428-32 [9865828.001]
  • [Cites] J Am Acad Dermatol. 1995 May;32(5 Pt 1):711-6 [7722013.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):119-22 [10697267.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):579-86 [10757407.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):745-50 [12090423.001]
  • [Cites] Acta Cytol. 2002 Jul-Aug;46(4):651-8 [12146025.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):801-6 [12817426.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):581-4 [1399140.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):725-31 [14608899.001]
  • [Cites] Int Rev Cytol. 1975;41:87-172 [166046.001]
  • [Cites] J Histochem Cytochem. 1991 Jul;39(7):927-36 [1865110.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):7162-7 [2582456.001]
  • [Cites] J Steroid Biochem. 1987 Mar;26(3):393-7 [3495702.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):539-42 [4007019.001]
  • [Cites] J Pathol. 1993 May;170(1):31-5 [8100853.001]
  • [Cites] J Histochem Cytochem. 1994 Jun;42(6):783-8 [8189040.001]
  • [Cites] Hum Pathol. 1993 Jan;24(1):90-5 [8418017.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] Mod Pathol. 1995 Dec;8(9):897-901 [8751328.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1175-80 [8883401.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3803-6 [9042261.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):839-45 [9267828.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1033-8 [9831198.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1122-6 [9831211.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • (PMID = 17020615.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1601970
  •  go-up   go-down


69. Shintaku WH, Venturin JS, Yepes JF: Application of advanced imaging modalities for the diagnosis of metastatic adenocarcinoma of the lungs in the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun;107(6):e37-41
MedlinePlus Health Information. consumer health - Temporomandibular Joint Dysfunction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of advanced imaging modalities for the diagnosis of metastatic adenocarcinoma of the lungs in the temporomandibular joint.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Mandibular Neoplasms / secondary. Temporomandibular Joint / pathology. Temporomandibular Joint Disorders / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464641.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R: Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park); 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
  • Erlotinib (Tarceva) is a human epidermal growth factor receptor type 1/epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor initially approved by the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of at least one prior chemotherapy regimen.
  • In this report, we present the pivotal study that led to the approval of erlotinib in combination with gemcitabine (Gemzar) in patients with locally advanced/metastatic chemonaive pancreatic cancer patients.
  • Physicians and patients now have a new option for the treatment of locally advanced/metastatic adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18247017.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


71. Vemulakonda VM, Lendvay TS, Shnorhavorian M, Joyner BD, Kaplan H, Mitchell ME, Grady RW: Metastatic adenocarcinoma after augmentation gastrocystoplasty. J Urol; 2008 Mar;179(3):1094-6; discussion 1097
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma after augmentation gastrocystoplasty.
  • To define better the risk of malignancy associated with gastric augmentation and the appropriate surveillance protocol for these patients, we describe our experience in 2 patients with metastatic adenocarcinoma following gastrocystoplasty.
  • Both patients had metastatic disease at initial presentation.
  • [MeSH-major] Adenocarcinoma / etiology. Stomach Neoplasms / etiology. Urinary Bladder Neoplasms / etiology. Urologic Surgical Procedures / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206936.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Daliakopoulos SI, Klimatsidas MN, Korfer R: Solitary metastatic adenocarcinoma of the sternum treated by total sternectomy and chest wall reconstruction using a Gore-Tex patch and myocutaneous flap: a case report. J Med Case Rep; 2010;4:75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary metastatic adenocarcinoma of the sternum treated by total sternectomy and chest wall reconstruction using a Gore-Tex patch and myocutaneous flap: a case report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1992 Feb;18(1):49-52 [1371103.001]
  • [Cites] Surg Today. 2006;36(2):180-3 [16440168.001]
  • [Cites] Am J Med. 1986 Sep;81(3):381-6 [2428242.001]
  • [Cites] Gan No Rinsho. 1989 Dec;35(15):1735-8 [2607606.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):158-61 [2916936.001]
  • [Cites] J Nucl Med. 1988 Mar;29(3):324-8 [3346742.001]
  • [Cites] Cancer. 1988 Oct 1;62(7):1397-401 [3416279.001]
  • [Cites] Prog Clin Cancer. 1967;3:1-18 [4966305.001]
  • [Cites] Clin Nucl Med. 1983 Aug;8(8):373-4 [6313272.001]
  • [Cites] Plast Reconstr Surg. 1984 Feb;73(2):240-8 [6695023.001]
  • [Cites] Ann Surg. 1983 Mar;197(3):284-7 [6830336.001]
  • [Cites] Int Surg. 1993 Jul-Sep;78(3):221-4 [8276545.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jan;111(1):96-105; discussion 105-6 [8551793.001]
  • [Cites] Ann Surg Oncol. 1996 Mar;3(2):162-8 [8646517.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):588-91; discussion 591-2 [10047664.001]
  • [Cites] Eur J Surg. 2000 Jan;166(1):92-4 [10688226.001]
  • [Cites] Ann Surg Oncol. 2002 Jun;9(5):472-9 [12052759.001]
  • [Cites] J Surg Oncol. 1992 Mar;49(3):189-95 [1548892.001]
  • (PMID = 20193081.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2844379
  •  go-up   go-down


73. Lu CC, Lin HF, Lee HS, Kao WY: Metastatic colon cancer presenting as Pancoast's disease. Am J Surg; 2009 May;197(5):e51-2
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colon cancer presenting as Pancoast's disease.
  • We report a rare case of metastatic adenocarcinoma of the sigmoid colon that presented as Pancoast's disease.
  • [MeSH-major] Adenocarcinoma / secondary. Pancoast Syndrome / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217605.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Sato T, Soejima K, Nakayama S, Satomi R, Sayama K, Asano K: [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):765-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung].
  • A 76-year-old woman with multiple bone metastases from lung adenocarcinoma was admitted due to a pathological femoral fracture.
  • Fat embolism syndrome should be considered as a differential diagnosis if consciousness disturbance and respiratory failure occur in patients with metastatic bone carcinoma and pathological long bone fractures.
  • [MeSH-major] Adenocarcinoma / complications. Embolism, Fat / etiology. Femoral Fractures / etiology. Fractures, Spontaneous / etiology. Lung Neoplasms / complications

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066866.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Doroshow JH, McCoy S, Macdonald JS, Issell BF, Patel T, Cobb PW, Yost KJ, Abbruzzese JL: Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. Invest New Drugs; 2006 Nov;24(6):537-42
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
  • From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Sep 1;76(5):715-9 [8625171.001]
  • [Cites] Anticancer Drugs. 2002 Jun;13(5):451-60 [12045456.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1150-6 [3498014.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):541-8 [1548519.001]
  • [Cites] Invest New Drugs. 1993 Nov;11(4):333-4 [8157475.001]
  • [Cites] Invest New Drugs. 1997;15(3):261-4 [9387050.001]
  • [Cites] Cancer Res. 1984 Oct;44(10):4667-9 [6331882.001]
  • [Cites] Am J Clin Oncol. 1995 Dec;18(6):484-7 [8526189.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):37-41 [12576922.001]
  • [Cites] Chemioterapia. 1985 Oct;4(5):377-82 [3878232.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Cancer Res. 1982 Oct;42(10):3964-70 [7104997.001]
  • [Cites] Biochem Pharmacol. 1992 Jun 23;43(12):2543-9 [1378737.001]
  • [Cites] Gastric Cancer. 2002;5 Suppl 1:35-40 [12772886.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):167-77 [10623707.001]
  • [Cites] Clin Pharmacol Ther. 1980 Aug;28(2):235-46 [7398191.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):383-7 [12598342.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):997-1001 [12966415.001]
  • [Cites] Med Oncol. 1999 Dec;16(4):261-6 [10618689.001]
  • [Cites] Cancer Treat Rep. 1986 Jun;70(6):745-50 [3731137.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1310-7 [2671287.001]
  • [Cites] Acta Oncol. 1996;35(2):207-12 [8639317.001]
  • [Cites] Ann Oncol. 2001 Nov;12 (11):1575-80 [11822757.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):157-62 [2909757.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):368-81 [8996164.001]
  • [Cites] Curr Oncol Rep. 2003 May;5(3):210-8 [12667418.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 20;83(6):437-41 [1999851.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1511-7 [9193347.001]
  • (PMID = 16832602.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76462
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PN 401; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; WHI7HQ7H85 / Uridine
  •  go-up   go-down


76. Amato RJ, Teh BS, Henary H, Khan M, Saxena S: A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol Oncol; 2009 Mar-Apr;27(2):165-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
  • If expansion of an androgen-independent clone present during androgen deprivation mediates the transformation from an androgen-dependent to an androgen-independent phenotype, combination chemohormonal therapy would be effective initial treatment for locally advanced or metastatic prostate cancers.
  • MATERIALS AND METHODS: Chemohormonal therapy outcomes were retrospectively evaluated in men with locally advanced or metastatic prostate cancer seen at our institution between January 2001 and February 2003.
  • CONCLUSIONS: Combination chemohormonal therapy for locally advanced or metastatic prostate cancer safely and effectively reduces PSA levels and increases OS.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367115.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


77. Grenader T, Goldberg A, Gabizon A: Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel. Anticancer Drugs; 2009 Oct;20(9):845-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / pathology. Liver Diseases / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633535.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


78. Lath CO, Khanna PC, Gadewar S, Patkar DP: Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma. Australas Radiol; 2005 Dec;49(6):497-500
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma.
  • We report an unusual case of extra-axial metastatic adenocarcinoma of the prostate that closely simulated a frontal, parasagittal, dural-based meningioma.
  • Such tumours, which satisfy several criteria for a diagnosis of meningioma, but which have proved instead to be metastatic adenocarcinoma of the prostate, form the focus of our report.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351616.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


79. Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, Daum S, Flieger D, Seufferlein T, Galle PR, Hoehler T, Arbeitsgemeinschaft Internistische Onkologie, Germany: A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol; 2010 Jan;21(1):71-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
  • BACKGROUND: The combination of irinotecan with 5-fluorouracil demonstrates efficacy with tolerable safety in the first-line treatment of metastatic gastroesophageal cancer (mGC).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605504.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


80. Bhanote M, Choksi M, Cassar P, Edelman M, DellaRatta R, Staszewski H: Metastatic adenocarcinoma of the colon and follicular lymphoma within the same lymph node: a case report and review of the literature. Int J Gastrointest Cancer; 2005;36(3):171-5
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the colon and follicular lymphoma within the same lymph node: a case report and review of the literature.
  • Concomitant adenocarcinoma and non-Hodgkin's lymphoma, both located in the intestinal tract, are unusual.
  • One lymph node was involved by both adenocarcinoma and follicular lymphoma.
  • To our knowledge, this is the fifteenth reported case of concurrent adenocarcinoma and non-Hodgkin's lymphoma of the intestine, but this is the first case with involvement of follicular lymphoma and adenocarcinoma within the same lymph node.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lymph Nodes / pathology. Lymphoma, Follicular / pathology. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):822-4 [6389052.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):E64-6 [12562254.001]
  • [Cites] Postgrad Med J. 1995 Jul;71(837):443 [7567744.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):811-7 [11504842.001]
  • [Cites] Gastroenterology. 1947 Jun;8(6):695-710 [20251622.001]
  • [Cites] Am J Gastroenterol. 1983 Jun;78(6):341-5 [6859012.001]
  • [Cites] J Clin Pathol. 1960 Nov;13(6):483-9 [16810961.001]
  • [Cites] Surg Clin North Am. 1959 Jun;39(3):725-35 [13659385.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):28-9 [9167378.001]
  • (PMID = 16720913.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA: Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol; 2006 Jan 20;24(3):379-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
  • The objectives of this study were to determine safety and efficacy in patients with metastatic pancreatic cancer treated with FDR gemcitabine in combination with low-dose cisplatin.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with metastatic pancreatic adenocarcinoma were treated with a combination of gemcitabine 1,000 mg/m2 at 10 mg/m2/min together with cisplatin 20 mg/m2 on days 1 and 8 of a 21-day cycle.
  • CONCLUSION: The combination of FDR gemcitabine and cisplatin is well tolerated and appears to be an acceptable, albeit not clearly superior, alternative to other gemcitabine/platinum regimens for the treatment of metastatic pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jan 20;24(3):327-9 [16344312.001]
  • (PMID = 16344320.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Huang B-, Chang C-, Hsu Y-: Multiple extra-axial adenocarcinomas mimicking meningiomas: a case report. Br J Neurosurg; 2008 Feb;22(1):123-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathological examination revealed metastatic adenocarcinoma of both lesions.
  • Metastatic adenocarcinoma should be considered in the differential diagnosis of dural-base lesions and the definitive diagnosis should only be established after the histopathological report.
  • [MeSH-major] Adenocarcinoma / secondary. Infarction, Middle Cerebral Artery / diagnosis. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Optic Nerve Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852111.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Gomes AC, Neto PJ, de Oliveira e Silva ED, Sávio E, Neto IC: Metastatic adenocarcinoma involving several bones of the body and the cranio-maxillofacial region: a case report. J Can Dent Assoc; 2009 Apr;75(3):211-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma involving several bones of the body and the cranio-maxillofacial region: a case report.
  • These metastatic tumours are most often located in the mandible, and the majority of these in the molar region.
  • The most common primary sources of metastatic tumours found in the oral region are the lung, kidney and prostate gland for the males, and the breast, genital organs and kidneys for females.
  • We present the case of a 51-year-old woman with metastatic adenocarcinoma involving the condyle and mandible, and other bones of the body.
  • [MeSH-major] Adenocarcinoma / secondary. Mandibular Neoplasms / secondary. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356321.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


84. Pandya NK, Auerbach JD, Baldwin K, Lackman RD, Chin KR: Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report. Spine (Phila Pa 1976); 2006 Nov 15;31(24):E920-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report.
  • SUMMARY OF BACKGROUND DATA: To our knowledge, there have been no previous reports of spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine.
  • The patient's mass was found to be breast adenocarcinoma metastatic to osteochondromas of the spine.
  • CONCLUSIONS: When faced with a patient with a history of multiple hereditary exostoses with new onset of myelopathic symptoms and a mass compressing the spinal cord, the clinician's differential should be broad and always initially include a metastatic lesion, osteochondroma, or chondrosarcoma.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / diagnosis. Exostoses, Multiple Hereditary / complications. Neoplasms, Unknown Primary / diagnosis. Spinal Cord Compression / etiology. Spinal Neoplasms / secondary. Thoracic Vertebrae / surgery


85. Wolff K, Wein A, Reulbach U, Männlein G, Brückl V, Meier C, Ostermeier N, Schwab SA, Horbach T, Hohenberger W, Hahn EG, Boxberger F: Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs; 2009 Mar;20(3):165-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
  • The aim of this phase II study was to evaluate the efficacy and safety of 5-fluorouracil/folinic acid (AIO regimen) plus irinotecan in patients with locally advanced or metastatic carcinoma of the oesophagus.
  • Last date of evaluation: 28 February 2007; n=24; adenocarcinoma: n=13, squamous cell carcinoma (SCC): n=11; UICC III/IV: 3/21; grading G1/G2/G3/G4: 0/8/12/4; median age: 58 years (range 44-75); men/women: 19/5; Eastern Cooperative Oncology Group index 0/1/2: 3/17/4; applications: 460.
  • Total median survival: 13.6 months (median survival of adenocarcinoma: 20.3 months, median survival of SCC: 10.0 months).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125117.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Badia Castello M, Trujillano Cabello J, Serviá Goixart L, Tarragona Foradada J, Panades Siurana MJ, Amoròs Galito E: Occult donor metastatic adenocarcinoma. Contribution of the forensic autopsy. A case report. Ann Transplant; 2010 Jan-Mar;15(1):67-71
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult donor metastatic adenocarcinoma. Contribution of the forensic autopsy. A case report.
  • Histological examination confirmed the presence of a metastatic adenocarcinoma in the lung 7 days after both kidneys had been transplanted.
  • [MeSH-major] Adenocarcinoma / etiology. Kidney Transplantation / adverse effects. Neoplasms / etiology. Nephrectomy / adverse effects. Tissue Donors

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305322.001).
  • [ISSN] 2329-0358
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


87. Moreno M, Moreno A, Tomé C: Sentinel lymph node biopsy in adenocarcinoma of minor salivary gland. Oral Oncol; 2008 Mar;44(3):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy in adenocarcinoma of minor salivary gland.
  • Adenocarcinoma of the minor salivary gland (MSG) is a rare neoplasm.
  • Microscopically, the neoplasms classified as adenocarcinoma not otherwise specified (NOS) are a histologically heterogeneous group: they vary from highly anaplastic adenocarcinoma to moderate and well-differentiated lesions.
  • This report describes a case of adenocarcinoma of MSG occurring in the buccal mucosa of a 24-year-old male.
  • In the histological examination of sentinel lymph node (SLN) there was no evidence of metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Glands, Minor / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17467330.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Cortés González JR, Garza R, Martínez R, Gómez L: [Prostate adenocarcinoma metastatic to penis]. Actas Urol Esp; 2006 Sep;30(8):832-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate adenocarcinoma metastatic to penis].
  • [Transliterated title] Adenocarcinoma de próstata metastático a pene.
  • We present one case of a patient with painless metastatic nodules on the penis secondary to a prostate cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Urol Esp. 2006 Oct;30(9):962-4 [17175940.001]
  • (PMID = 17078582.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 6
  •  go-up   go-down


89. Malik I, Bernal P, Byrd J: A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction. Cancer Invest; 2010 Oct;28(8):833-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / toxicity. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20839949.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


90. Jatoi A, Foster NR, Egner JR, Burch PA, Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR, Alberts SR: Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. Int J Oncol; 2010 Mar;36(3):601-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials.
  • Whether elderly patients with metastatic esophageal, gastroesophageal, and gastric cancer do as well with chemotherapy as their younger counterparts was investigated in this pooled analysis.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Esophagogastric Junction / pathology. Stomach Neoplasms / therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Jun 1;112(11 Suppl):2569-76 [18428204.001]
  • [Cites] J Thorac Oncol. 2008 May;3(5):516-20 [18449005.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3243-50 [17713823.001]
  • [Cites] J Gastroenterol. 2008;43(5):345-51 [18592152.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Am J Clin Oncol. 2007 Dec;30(6):607-11 [18091055.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2350-7 [18467727.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):652-6 [16497828.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Sep;32(3):445-8 [17643999.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1823-7 [17533399.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(2-3):115-23 [12794247.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3205-9 [17664467.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 Jun;33(6):1096-104 [18407509.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3699-704 [17704418.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1929-36 [18430912.001]
  • [Cites] JAMA. 2007 Dec 12;298(22):2634-43 [18073359.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1888-91 [8909307.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1491-4 [2311061.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Dis Esophagus. 2007;20(4):297-300 [17617877.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):29-34 [16303863.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):505-8 [10521068.001]
  • (PMID = 20126980.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA035267; United States / NCI NIH HHS / CA / U10 CA037417; United States / NCI NIH HHS / CA / K24 CA131099; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA035269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / U10 CA060276; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / U10 CA180821; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / K24CA131099; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA-52654; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / U10 CA063849; United States / NCI NIH HHS / CA / U10 CA180882; United States / NCI NIH HHS / CA / CA-35119; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA-3510; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / N01 CA015083; United States / NCI NIH HHS / CA / U10 CA035103
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  •  go-up   go-down


91. Anis A, Narayan RL, Kapa S, Klapholz M, Saric M: Metastatic signet ring adenocarcinoma: an unusual cause of cardiac constriction. Mt Sinai J Med; 2006 Oct;73(6):898-901
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic signet ring adenocarcinoma: an unusual cause of cardiac constriction.
  • Pericardial constriction secondary to metastatic adenocarcinoma is exceedingly rare.
  • We present the first recorded case of pericardial constriction secondary to metastatic signet-ring mucinous adenocarcinoma diagnosed by echocardiography.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117320.001).
  • [ISSN] 0027-2507
  • [Journal-full-title] The Mount Sinai journal of medicine, New York
  • [ISO-abbreviation] Mt. Sinai J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Tumuluri K, Sharkawi E, Bindra M, Olver JM: Esophageal adenocarcinoma metastatic to the orbit. Ophthal Plast Reconstr Surg; 2006 Mar-Apr;22(2):151-2
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinoma metastatic to the orbit.
  • A 75-year-old woman presented with orbital and ethmoidal metastases from an esophageal adenocarcinoma 6 months after diagnosis of the primary.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Orbital Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550071.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Peregrin-Alvarez I, Akl MN, Morrow CP, Magrina JF: Metastatic and recurrent adenocarcinoma of the uterine cervix: a long-term survival of 16 years. Eur J Gynaecol Oncol; 2010;31(3):333-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic and recurrent adenocarcinoma of the uterine cervix: a long-term survival of 16 years.
  • PURPOSE OF INVESTIGATION: Recurrent metastatic adenocarcinoma of the cervix is associated with an extremely poor prognosis.
  • CASE REPORT: We report a case of a 43-year-old patient with Stage IB adenocarcinoma of the cervix.
  • She had multiple metastatic recurrence episodes salvaged with several radical surgeries, external and intraoperative irradiation, and chemotherapy over a survival period of 16 years.
  • CONCLUSION: We conclude that long-term multi-modal salvage treatment may achieve longer survival in rare cases with recurrent metastatic adenocarcinoma of the cervix.
  • [MeSH-major] Adenocarcinoma / therapy. Neoplasm Recurrence, Local / therapy. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077482.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


94. Wright JL, Lin DW, Dewan P, Montgomery RB: Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Int J Urol; 2005 Nov;12(11):1012-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
  • We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents, Phytogenic / adverse effects. Paclitaxel / adverse effects. Prostatic Neoplasms / therapy. Tumor Lysis Syndrome / etiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351664.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; EC 3.4.21.77 / Prostate-Specific Antigen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


95. Myrehaug S, Bezjak A: Rapidly progressive bone destruction of the finger as first presentation of systemic metastases from lung cancer. BMJ Case Rep; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a man with locally advanced lung adenocarcinoma and no evidence of metastatic disease presenting with rapid onset pain and swelling of his right second finger.
  • He clinically worsened, and upon biopsy was found to have metastatic adenocarcinoma of the digit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22242077.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029992
  •  go-up   go-down


96. Sawada T, Takahashi H, Hasatani K, Yoshida I, Oyama O, Inoue R, Miwa K, Kawashiri MA, Misawa K, Kyoi M, Miyamoto S: Tumor-to-tumor metastasis: report of an autopsy case of lung adenocarcinoma metastasizing to renal cell carcinoma. Intern Med; 2009;48(17):1525-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis: report of an autopsy case of lung adenocarcinoma metastasizing to renal cell carcinoma.
  • Lung cancer metastatic to renal cell carcinoma represents the most common combination of such tumor-to-tumor metastases.
  • We present the autopsy case of a 97-year-old woman with metastatic adenocarcinoma of the lung to renal cell carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / diagnosis. Kidney Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721297.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


97. Yunker JJ, Vicinanzo MG, Braswell RA, Read RW, Goldin GF, Long JA: Unusual presentation of gastric adenocarcinoma metastatic to the orbit. Ophthal Plast Reconstr Surg; 2006 Nov-Dec;22(6):490-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of gastric adenocarcinoma metastatic to the orbit.
  • Histopathology revealed a mucinous adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Orbital Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117115.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kaur J, Dey P: Micronucleus to distinguish adenocarcinoma from reactive mesothelial cell in effusion fluid. Diagn Cytopathol; 2010 Mar;38(3):177-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronucleus to distinguish adenocarcinoma from reactive mesothelial cell in effusion fluid.
  • To evaluate the role of the scoring of micronucleated cell (MNC) to distinguish reactive mesothelial cells from adenocarcinoma cells in effusion fluid.
  • A total of 20 cases of unequivocal metastatic adenocarcinoma and 15 controls with reactive mesothelial cell proliferation in ascetic fluid were selected for scoring of the MNC.
  • The mean number of MNC in metastatic adenocarcinoma and reactive mesothelial cells were 21 + 6.53 and 2.93 + 2.63, respectively, per 1000 cells.
  • Micronuclei frequency was significantly increased in adenocarcinoma patients compared with controls (Student's t-test, P < 0.001).
  • The scoring of MNC can be used as an additional biomarker and to discriminate between benign reactive mesothelial cells versus metastatic adenocarcinoma in effusion fluids in difficult situation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ascites / diagnosis. Micronuclei, Chromosome-Defective. Neoplasms, Mesothelial / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19693939.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. bin Sabir Husin Athar PP, bte Ahmad Norhan N, bin Saim L, bin Md Rose I, bte Ramli R: Metastasis to the sinonasal tract from sigmoid colon adenocarcinoma. Ann Acad Med Singapore; 2008 Sep;37(9):788-3
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the sinonasal tract from sigmoid colon adenocarcinoma.
  • INTRODUCTION: Metastatic adenocarcinoma from the gastrointestinal tract to the sinonasal tract is rare.
  • The histological morphology of this lesion is indistinguishable from the colonic variant of primary sinus adenocarcinoma or intestinal-type adenocarcinoma (ITAC).
  • CLINICAL PICTURE: This is a report of a case of metastatic adenocarcinoma of colorectal origin to the paranasal sinuses in a 52-year-old female who was previously treated for adenocarcinoma of the sigmoid colon.
  • The sinonasal neoplastic tissue showed marked positivity for carcinoembryonic antigen and expressed cytokeratin 20, which differentiates metastatic colonic adenocarcinoma from ITAC.
  • CONCLUSION: Distinguishing metastatic adenocarcinoma from gastrointestinal tract from ITAC can be difficult.
  • It is important to recognise these as metastatic lesions as the treatment is mainly palliative.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989497.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-20
  •  go-up   go-down


100. Perpiñán D, Steffen D, Napier JE: Pulmonary adenocarcinoma and endogenous lipid pneumonia in a common genet (Genetta genetta). J Zoo Wildl Med; 2010 Dec;41(4):710-2
MedlinePlus Health Information. consumer health - Pneumonia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenocarcinoma and endogenous lipid pneumonia in a common genet (Genetta genetta).
  • The histologic diagnosis was metastatic adenocarcinoma with associated endogenous lipid pneumonia.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Pneumonia / veterinary. Viverridae

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21370654.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down






Advertisement